Bain Capital Life Sciences Investors’s Atea Pharmaceuticals AVIR Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$12.7M	Sell	2,360,638 -125,000	-5%	-$574K	1.15%	16
2025 Q4	$8.87M	Hold	2,485,638	–	–	0.68%	16
2025 Q3	$7.21M	Hold	2,485,638	–	–	0.48%	16
2025 Q2	$8.95M	Hold	2,485,638	–	–	1.12%	16
2025 Q1	$7.43M	Hold	2,485,638	–	–	1.1%	13
2024 Q4	$8.33M	Hold	2,485,638	–	–	0.98%	16
2024 Q3	$8.33M	Hold	2,485,638	–	–	0.87%	15
2024 Q2	$8.23M	Hold	2,485,638	–	–	0.9%	17
2024 Q1	$10M	Hold	2,485,638	–	–	0.81%	19
2023 Q4	$7.58M	Hold	2,485,638	–	–	0.73%	21
2023 Q3	$7.46M	Hold	2,485,638	–	–	0.83%	24
2023 Q2	$9.3M	Hold	2,485,638	–	–	0.96%	22
2023 Q1	$8.33M	Hold	2,485,638	–	–	1.04%	25
2022 Q4	$12M	Hold	2,485,638	–	–	1.34%	21
2022 Q3	$14.1M	Hold	2,485,638	–	–	1.69%	19
2022 Q2	$17.6M	Hold	2,485,638	–	–	2.07%	16
2022 Q1	$17.9M	Hold	2,485,638	–	–	1.74%	16
2021 Q4	$22.2M	Sell	2,485,638 -1,214,362	-33%	-$18.9M	1.76%	15
2021 Q3	$130M	Sell	3,700,000 -1,915,659	-34%	-$53.1M	8.05%	4
2021 Q2	$121M	Hold	5,615,659	–	–	7.9%	2
2021 Q1	$347M	Hold	5,615,659	–	–	19.64%	2
2020 Q4	$235M	Buy	+5,615,659	New	+$181M	14.73%	2

Other funds holding AVIR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bain Capital Life Sciences Investors's AVIR Position: Q1 2026 in Review

Bain Capital Life Sciences Investors reduced its Atea Pharmaceuticals (AVIR) stake by 5% in Q1 2026, selling an estimated $574K and leaving 2,360,638 shares worth $12.7M. The position accounts for 1.15% of the portfolio, ranked #16.

Bain Capital Life Sciences Investors first reported a position in AVIR in Q4 2020 and has held it in 22 quarters since. The position peaked at $347M in Q1 2021. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

Bain Capital Life Sciences Investors held 2,360,638 shares of Atea Pharmaceuticals worth $12.7M as of Q1 2026.
Bain Capital Life Sciences Investors sold 125,000 Atea Pharmaceuticals shares in Q1 2026, an estimated $574K.
Atea Pharmaceuticals made up 1.15% of Bain Capital Life Sciences Investors's portfolio in Q1 2026, its #16 holding.
Bain Capital Life Sciences Investors first reported a position in Atea Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
Bain Capital Life Sciences Investors's Atea Pharmaceuticals position peaked at $347M in Q1 2021.
127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on Bain Capital Life Sciences Investors's 13F filing for Q1 2026, filed 15 May 2026.